Dow Jones
38 571,03 -115,27 (-0,30 %) Nasdaq
16 828,67 +93,65 (+0,56 %) Nikkei 225
38 749,25 -173,78 (-0,45 %) EUR/USD
1,0912 +0,0006 (+0,05 %) HANG SENG
18 424,45 +21,45 (+0,12 %) Bitcoin EUR
63 399,42 +729,27 (+1,16 %)
H. Lundbeck A/S (HLUNBC.XC)
H. Lundbeck A/S
Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 5 681
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Charl van Zyl | President & CEO | 36,9M | S.O. | 1967 |
| Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions | 8,5M | S.O. | 1977 |
| Mr. Lars Bang | Executive Vice President of Product Development & Supply | 7,9M | S.O. | 1962 |
| Dr. Per Johan Luthman | Executive Vice President of Research & Development | 8,8M | S.O. | 1959 |
| Dr. Tarek Samad Ph.D. | Senior VP & Head of Research | S.O. | S.O. | S.O. |
| Mr. Palle Holm Olesen | Chief Specialist & VP of Investor Relations | S.O. | S.O. | S.O. |
| Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs | S.O. | S.O. | 1975 |
| Ms. Dianne Holto | Executive Vice President of People & Organization | S.O. | S.O. | 1973 |
| Mr. Ole Chrintz | Senior Vice President of International Markets | S.O. | S.O. | 1958 |
| Dr. Rupert Sandbrink M.D., Ph.D. | Senior VP & Head of Clinical Development | S.O. | S.O. | 1964 |
Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Gouvernance d’entreprise
L’ISS Governance QualityScore de H. Lundbeck A/S en date du 1 mai 2024 est 3. Les scores principaux sont Audit : 4; Société : 5; Droits des actionnaires : 9; Compensation : 1.
